Constellium SE
NYSE:CSTMAluminum
+$0.32 today
- Market cap
- $2.88B
- Beta
- 1.54
- P/E (TTM)
- 10.7
- EPS (TTM)
- $3.17
Volume 1.46M
Average 2.27M
CSTM Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Constellium SENYSE: CSTM
Research & Development · Q3 FY2026 · quarter ended Sep 2026
Research & development grows 0.0% year over year
Q3 FY2026 research & development of $12M rose 0.0% year over year. Sequentially, it fell 14.3% from the prior quarter. Over 3 fiscal years it compounded at +6.1% a year.
Context
- Research & development amounted to 0.6% of revenue in FY2025, unchanged from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
Mixed currencies · from the income statement
- Latest · FY2025
- 51M USD
- Year-over-year change
- —
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51M | — |
| FY2024 | 2024-12-31 | 47.32M | +0.1% |
| FY2023 | 2023-12-31 | 47.25M | +10.5% |
| FY2022 | 2022-12-31 | 42.75M | -3.2% |
| FY2021 | 2021-12-31 | 44.16M | — |
Research & Development vs competitors
How CSTM compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Research & development amounts to 0.5% of revenue for CSTM, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $101.2M USD | +59.6% | — | 2.4% | |
| LTM Mar 2026 | R$60.87M BRL | +27.5% | +12.1% | 0.1% | |
| LTM Jun 2026 | $55M USD | +3.8% | -0.6% | 3.0% | |
| LTM Sep 2026 | $53M USD | — | +6.1% | 0.5% | |
| LTM Jul 2026 | $25.74M USD | -5.0% | -3.6% | 1.2% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| LTM Sep 2026 | $0 USD | — | — | 0.0% | |
| LTM Jun 2026 | $0 USD | -100.0% | — | 0.0% | |
| FY2026 | ZAR 0 ZAR | — | — | 0.0% | |
| Peer median (excluding CSTM) | — | +3.8% | -0.6% | 0.0% | |
Competitors are the stored peer set for CSTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 · EUR | FY2022 Dec 2022 · EUR | FY2023 Dec 2023 · EUR | FY2024 Dec 2024 · EUR | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Revenue | 6.97B | 7.93B | 7.11B | 7.08B | 8.45B |
| Cost of Revenue | 6.21B | 7.03B | 6.15B | 6.18B | 7.59B |
| Gross Profit | 751.79M | 894.89M | 958.68M | 905.83M | 857M |
| Gross Margin | 10.8% | 11.3% | 13.5% | 12.8% | 10.1% |
| Research & Development | 44.16M | 42.75M | 47.25M | 47.32M | 51M |
| Selling, General & Admin | 292.11M | 263.91M | 288.06M | 302.26M | 332M |
| Operating Expenses | 203.8M | 576.15M | 607.92M | 643.16M | 383M |
| Depreciation & Amortization | 302.3M | 287M | 275.07M | 293.57M | 330M |
| EBITDA | 802.74M | 518.39M | 583.12M | 523.41M | 852M |
| EBITDA Margin | 11.5% | 6.5% | 8.2% | 7.4% | 10.1% |
| Operating Income | 547.99M | 318.74M | 350.76M | 262.67M | 474M |
| Operating Margin | 7.9% | 4.0% | 4.9% | 3.7% | 5.6% |
| Interest Income | 0 | 0 | 16M | 0 | 0 |
| Interest Expense | 154.84M | 126.12M | 115M | 112M | 114M |
| Other Income / Expenses | (189.08M) | (179.35M) | (139.94M) | (132.3M) | (66M) |
| Income Before Tax | 358.91M | 139.39M | 210.82M | 130.37M | 408M |
| Pre-Tax Margin | 5.2% | 1.8% | 3.0% | 1.8% | 4.8% |
| Income Tax Expense | 62.27M | (153.33M) | 68.15M | 72.43M | 133M |
| Net Income | 290.98M | 286.22M | 138.12M | 54.08M | 273M |
| Net Margin | 4.2% | 3.6% | 1.9% | 0.8% | 3.2% |
| EPS (Basic) | 1.82 | 2.00 | 0.84 | 0.37 | 1.95 |
| EPS (Diluted) | 1.75 | 1.96 | 0.84 | 0.37 | 1.92 |
| Weighted Avg Shares | 141M | 143.63M | 148.81M | 145.49M | 139.68M |
| Weighted Avg Shares (Diluted) | 147.17M | 146.61M | 149.24M | 147.44M | 141.94M |
Constellium SE
NYSE:CSTM
Intrinsic Alpha fair value
Locked
Current Price
$21.37
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.